No preview available from this publisher — open the full story below.
Generic GLP-1 drugmakers are anticipating a period of decelerated growth, reflecting evolving market dynamics and heightened competition. The initial boom for these medications may be plateauing as regulatory landscapes shift and consumer preferences lean towards newer,…
Market Samachar is a news aggregator. This article was originally published by indian-share-tips.com. Tap the button above to read the full story on their site.